Loading…
Wild Child WA Pty Ltd., a drug manufacturer, received an FDA Warning Letter on December 6, 2019, indicating significant regulatory compliance concerns. However, the specific violations and detailed subject matter cannot be determined from the available metadata. Based on the drug product classification, the violations likely relate to manufacturing, labeling, or quality control standards, though the exact nature and scope require review of the complete correspondence. The issuing office information is not available in the provided metadata.